Indivior (NASDAQ:INDV) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Indivior (NASDAQ:INDV) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $16.00 price target on the stock.

A number of other research firms have also recently commented on INDV. Craig Hallum decreased their price target on Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, October 11th. Piper Sandler restated an “overweight” rating and set a $16.00 price objective (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Trading Up 0.4 %

NASDAQ INDV opened at $12.20 on Tuesday. The firm’s fifty day simple moving average is $11.75 and its two-hundred day simple moving average is $11.02. The firm has a market capitalization of $1.68 billion, a P/E ratio of -304.92 and a beta of 0.74. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22.

Hedge Funds Weigh In On Indivior

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Indivior by 4.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company’s stock valued at $408,000 after purchasing an additional 1,888 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Indivior in the 4th quarter worth approximately $56,000. Cubist Systematic Strategies LLC raised its position in Indivior by 32.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after buying an additional 6,121 shares during the last quarter. Geode Capital Management LLC raised its position in Indivior by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 132,239 shares of the company’s stock worth $1,289,000 after buying an additional 9,500 shares during the last quarter. Finally, Stifel Financial Corp acquired a new stake in Indivior during the 3rd quarter valued at approximately $100,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.